THE IMPACT AND COSTS OF REIMBURSED SMOKING CESSATION USING VARENICLINE IN DENMARK
Author(s)
Poulsen PB, Randskov HJ, Dollerup JPfizer Denmark ApS., Ballerup, Denmark
Presentation Documents
OBJECTIVES: To show the economic consequences of implementing reimbursement for pharmacological smoking cessation, i.e. varenicline, in Denmark compared with future disease events avoided and corresponding savings in the healthcare sector and the society due to reduced smoking prevalence. METHODS: A costing template developed by the National Institute for Health and Clinical Excellence in United Kingdom for the implementation of varenicline in smoking cessation in the United Kingdom (http://guidance.nice.org.uk/TA123/CostTemplate/xls/English) was adjusted and applied for Denmark using Danish data on smokers, costs of pharmacological smoking cessation, costs of disease events, etc. and Danish reimbursement rules. RESULTS: The public health insurance costs in Denmark for reimbursing a quit-motivated smoker 12 weeks of prescribed varenicline will amount to 949-1,920 DKK (1 Euro = 7.45 DKK) with co-payment being lower for chronically ill persons. Assuming reimbursing 40,000 smokers will then be at a cost for the national health insurance between 38-77 million DKK. However, the benefit will be 9,000 abstinent persons, thus preventing respectively 2110, 3383 and 5214 disease events (50% COPD) after 2, 10 and 20 years, respectively. Accordingly after 2 years, the health care sector savings due to an avoided first acute hospital contact (DRG-charges for each disease) amount to 47 mill. DKK or 281 mill. DKK for the society, when health care savings after the first acute contact and production lost are included. At 20 years health care sector savings rise to 141 million DKK (or 846 million DKK in societal savings) due to 9000 abstinent persons. CONCLUSIONS: The study shows that break-even between higher health insurance costs (reimbursement of prescribed varenicline) and costs saved due to avoidance of the first acute hospital contact will for persons with a low reimbursement rate appear less than 2 years after initiation of smoking cessation. Varenicline is reimbursed in Sweden, UK, Ireland and Belgium, but not in Denmark.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PRS9
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders